Lineage Cell Therapeutics, Inc. Preferred Stock Dividends, Income Statement Impact
Lineage Cell Therapeutics, Inc. (LCTX) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2018-03-15
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2016-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2016-03-31 was $0.00.
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2016 was $0.00.
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2015 was -$415.00K, a 577.01% decline from fiscal 2014.
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2014 was $87.00K.
- Lineage Cell Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2013 was $0.00.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 3 month as first filed | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 6 month as first filed | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 9 month as first filed | Preferred Stock Dividends, Income Statement Impact 12 month | Preferred Stock Dividends, Income Statement Impact 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $0.00 derived: sum of 3 quarters · filed 2017-03-16 | $0.00 10-K · filed 2017-03-16 | ||||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-04 | $0.00 derived: sum of 2 quarters · filed 2016-11-04 | $0.00 10-Q · filed 2016-11-04 | -$830.00K derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | -$830.00K derived: sum of 3 quarters · filed 2018-03-15 | -$467.00K derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2017-03-16 | -$830.00K derived: sum of 2 quarters · filed 2018-03-15 | -$467.00K derived: sum of 3 quarters · filed 2018-03-15 | -$415.00K derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-12-31 | -$830.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$467.00K derived: sum of 2 quarters · filed 2018-03-15 | -$415.00K derived: sum of 3 quarters · filed 2018-03-15 | -$415.00K 10-K · filed 2018-03-15 | ||||
| 2015-09-30 | $363.00K 10-Q · filed 2016-11-04 | $415.00K derived: sum of 2 quarters · filed 2016-11-04 | $415.00K 10-Q · filed 2016-11-04 | |||||
| 2015-06-30 | $52.00K 10-Q · filed 2016-08-09 | $52.00K 10-Q · filed 2016-08-09 | ||||||
| 2014-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $87.00K derived: sum of 2 quarters · filed 2017-03-16 | $121.00K derived: sum of 3 quarters · filed 2017-03-16 | $87.00K 10-K · filed 2017-03-16 | $86.83K 10-K · filed 2015-03-11 | |||
| 2014-09-30 | $34.00K 10-Q · filed 2015-11-09 | $34.04K 10-Q · filed 2014-11-07 | $68.00K derived: sum of 2 quarters · filed 2015-11-09 | $34.00K 10-Q · filed 2015-11-09 | $34.04K 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $34.00K 10-Q · filed 2015-08-10 | $34.04K 10-Q · filed 2014-08-11 | $34.00K 10-Q · filed 2015-08-10 | $34.04K 10-Q · filed 2014-08-11 | ||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $0.00 derived: sum of 2 quarters · filed 2016-03-15 | $0.00 derived: sum of 3 quarters · filed 2016-03-15 | $0.00 10-K · filed 2016-03-15 | ||||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | $0.00 10-Q · filed 2014-11-07 | |||||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | ||||||
| 2012-12-31 | $0.00 10-K · filed 2015-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |